Rameda Pharmaceuticals
Nourhan Abdelgwad is an emerging professional in the pharmaceutical and healthcare sectors with diverse experience spanning multiple roles. Currently serving as a Trainee at Sandoz Egypt, as well as a Quality Assurance/Quality Control Trainee at European Egyptian Pharmaceutical Industries, Nourhan simultaneously holds positions as a Medical Representative Cosmotic Trainee at Vitocare and a Trainee at Rameda Pharmaceuticals. Previous experience includes serving as staff at Scincetopia and as a Community Pharmacist at Elsaraia Group since December 2019. Nourhan briefly worked as a Quality Assurance Specialist in March 2022. Educational endeavors include a degree in General Pharmacy from Faculty of Pharmacy, Alexandria University, projected for completion in 2023, along with ongoing programs at Ibn Sina Academy and various certifications from Google Skills, WHO, and other institutions.
This person is not in any teams
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.